blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3326641

EP3326641 - RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  27.06.2024
Database last updated on 03.04.2025
FormerThe patent has been granted
Status updated on  24.05.2019
FormerGrant of patent is intended
Status updated on  12.05.2019
FormerExamination is in progress
Status updated on  22.02.2019
FormerRequest for examination was made
Status updated on  27.04.2018
Most recent event   Tooltip17.01.2025Lapse of the patent in a contracting state
New state(s): NO		published on 19.02.2025  [2025/08]
Applicant(s)For all designated states
CureVac SE
Friedrich-Miescher-Straße 15
72076 Tübingen / DE
[2023/01]
Former [2021/10]For all designated states
CureVac AG
Friedrich-Miescher-Straße 15
72076 Tübingen / DE
Former [2018/22]For all designated states
CureVac AG
Paul-Ehrlich-Str. 15
72076 Tübingen / DE
Inventor(s)01 / Fotin-Mleczek, Mariola
c/o IP Department
CureVac AG
Paul Ehrlich Str. 15
72706 Tübingen / DE
02 / Kowalczyk, Aleksandra
c/o IP Department
CureVac AG
Paul Ehrlich Str. 15
72706 Tübingen / DE
03 / Heidenreich, Regina
c/o IP Department
CureVac AG
Paul Ehrlich Str. 15
72076 Tübingen / DE
04 / Baumhof, Patrick
c/o IP Department
CureVac AG
Paul Ehrlich Str. 15
72706 Tübingen / DE
05 / Probst, Jochen
c/o IP Department
CureVac AG
Paul Ehrlich Str. 15
72706 Tübingen / DE
06 / Kallen, Karl-Josef
c/o IP Department
CureVac AG
Paul Ehrlich Str. 15
72706 Tübingen / DE
 [2019/26]
Former [2018/22]01 / Fotin-Mleczek, Mariola
Chemnitzer Weg 10
71065 Sindelfingen / DE
02 / Kowalczyk, Aleksandra
Ostendstr. 82
70188 Stuttgart / DE
03 / Heidenreich, Regina
Birkenstr. 15
72072 Tübingen / DE
04 / Baumhof, Patrick
Erlenstr. 28
72144 Dusslingen / DE
05 / Probst, Jochen
In den Kirchhofländern 19
72649 Wolfschlugen / DE
06 / Kallen, Karl-Josef
Marienhofer Weg 24
50226 Königsdorf / DE
Representative(s)Graf von Stosch, Andreas, et al
Graf von Stosch
Patentanwaltsgesellschaft mbH
Prinzregentenstraße 22
80538 München / DE
[2018/22]
Application number, filing date17196250.922.04.2016
[2018/22]
Priority number, dateEP2015000119122.04.2015         Original published format: EP 15001191
[2018/22]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3326641
Date:30.05.2018
Language:EN
[2018/22]
Type: B1 Patent specification 
No.:EP3326641
Date:26.06.2019
Language:EN
[2019/26]
Search report(s)(Supplementary) European search report - dispatched on:EP09.04.2018
ClassificationIPC:A61K38/19, A61K31/7105, C07K14/52, A61K38/20, A61K39/00, C12N15/113, C12N15/117, A61P35/00
[2019/20]
CPC:
A61K31/7105 (EP,RU,US); A61K48/005 (CN,KR,US); A61K31/7088 (CN);
A61K31/713 (EP,US); A61K38/177 (EP,CN,KR,US); A61K38/1774 (EP,CN,US);
A61K38/19 (EP,CN,KR,RU,US); A61K38/191 (US); A61K38/20 (CN);
A61K38/208 (EP,KR,US); A61K39/0011 (CN); A61K39/12 (EP,US);
A61K39/145 (US); A61K39/39 (EP,US); A61K39/3955 (EP,KR,US);
A61K39/39558 (CN,KR,US); A61K45/06 (CN,KR,US); A61K48/0025 (US);
A61K48/0041 (KR,US); A61K9/0019 (CN,US); A61P35/00 (EP);
A61P43/00 (EP); C07K16/2818 (EP,KR,US); C07K16/2878 (US);
C07K16/2896 (EP,US); C07K16/30 (US); C07K16/34 (EP,US);
C12N15/113 (RU); C12N15/117 (KR,US); C12N7/00 (US);
C12Q1/6806 (RU); A61K2039/53 (EP,CN,US); A61K2039/54 (EP,CN,US);
A61K2039/55511 (EP,CN,US); A61K2039/55522 (EP,CN,US); A61K2039/55538 (EP,CN,US);
A61K2039/55561 (EP,US); A61K2039/585 (EP,CN,US); A61K2300/00 (KR);
C07K2317/75 (US); C07K2317/76 (US); C12N2310/17 (US);
C12N2320/30 (US); C12N2760/16034 (US); C12N2760/16134 (EP,US);
Y02A50/30 (EP,US) (-)
C-Set:
A61K31/7088, A61K2300/00 (CN);
A61K38/1774, A61K2300/00 (CN);
A61K38/177, A61K2300/00 (CN);
A61K38/19, A61K2300/00 (CN);
A61K38/20, A61K2300/00 (CN);
A61K39/0011, A61K2300/00 (CN);
A61K39/39558, A61K2300/00 (CN);
A61K39/3955, A61K2300/00 (EP,US)
(-)
Former IPC [2018/22]A61K38/19, C07K14/52, A61K38/20, A61K39/00, C12N15/113, C12N15/117, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/22]
TitleGerman:RNA-HALTIGE ZUSAMMENSETZUNG ZUR BEHANDLUNG VON TUMORERKRANKUNGEN[2018/22]
English:RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES[2018/22]
French:COMPOSITION CONTENANT UN ARN POUR LE TRAITEMENT DE MALADIES TUMORALES[2018/22]
Examination procedure12.10.2017Date on which the examining division has become responsible
24.10.2017Examination requested  [2018/22]
30.11.2018Amendment by applicant (claims and/or description)
27.02.2019Despatch of a communication from the examining division (Time limit: M02)
14.03.2019Reply to a communication from the examining division
13.05.2019Communication of intention to grant the patent
20.05.2019Fee for grant paid
20.05.2019Fee for publishing/printing paid
20.05.2019Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP16166757.1  / EP3173092
Divisional application(s)EP19181044.9  / EP3603661
Opposition(s)Opponent(s)01  24.03.2020  26.03.2020  ADMISSIBLE
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
Opponent's representative
Wichmann, Hendrik
Wuesthoff & Wuesthoff
Patentanwälte und Rechtsanwalt PartG mbB
Schweigerstraße 2
81541 München / DE
 02  26.03.2020  30.03.2020  ADMISSIBLE
Pfizer Inc.
66 Hudson Boulevard East
New York, NY 10001-2192 / US
Opponent's representative
Pfizer
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
 03  26.03.2020  30.03.2020  ADMISSIBLE
Grund, Dr., Martin
Steinsdorfstraße 2
80538 München / DE
Opponent's representative
Grund, Martin
Grund Intellectual Property Group
Patentanwälte und Solicitor PartG mbB
Steinsdorfstraße 2
80538 München / DE
 04  17.04.2020  24.05.2023  WITHDRAWN
Friedrich, Rainer
Breuer Friedrich Hahner Patentanwälte PartG mbB
Brienner Straße 1
80333 München / DE
Opponent's representative
Friedrich, Rainer
CSL Behring GmbH
Emil-von-Behring-Straße 76
35041 Marburg / DE
 [N/P]
Former [2023/46]
Opponent(s)01  24.03.2020  26.03.2020  ADMISSIBLE
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
Opponent's representative
Wichmann, Hendrik
Wuesthoff & Wuesthoff
Patentanwälte PartG mbB
Schweigerstraße 2
81541 München / DE
 02  26.03.2020  30.03.2020  ADMISSIBLE
Pfizer Inc.
66 Hudson Boulevard East
New York, NY 10001-2192 / US
Opponent's representative
Pfizer
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
 03  26.03.2020  30.03.2020  ADMISSIBLE
Grund, Dr., Martin
Steinsdorfstraße 2
80538 München / DE
Opponent's representative
Grund, Martin
Grund Intellectual Property Group
Patentanwälte und Solicitor PartG mbB
Steinsdorfstraße 2
80538 München / DE
 04  17.04.2020  24.05.2023  WITHDRAWN
Friedrich, Rainer
Breuer Friedrich Hahner Patentanwälte PartG mbB
Brienner Straße 1
80333 München / DE
Opponent's representative
Friedrich, Rainer
CSL Behring GmbH
Emil-von-Behring-Straße 76
35041 Marburg / DE
Former [2023/29]
Opponent(s)01  24.03.2020  26.03.2020  ADMISSIBLE
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
Opponent's representative
Wichmann, Hendrik
Wuesthoff & Wuesthoff
Patentanwälte PartG mbB
Schweigerstraße 2
81541 München / DE
 02  26.03.2020  30.03.2020  ADMISSIBLE
Pfizer Inc.
66 Hudson Boulevard East
New York, NY 10001-2192 / US
Opponent's representative
Pfizer
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
 03  26.03.2020  30.03.2020  ADMISSIBLE
Grund, Dr., Martin
Nikolaistr. 15
80802 Munich / DE
Opponent's representative
Grund, Martin
Grund Intellectual Property Group
Patentanwälte und Solicitor PartG mbB
Steinsdorfstraße 2
80538 München / DE
 04  17.04.2020  24.05.2023  WITHDRAWN
Friedrich, Rainer
Breuer Friedrich Hahner Patentanwälte PartG mbB
Brienner Straße 1
80333 München / DE
Opponent's representative
Friedrich, Rainer
CSL Behring GmbH
Emil-von-Behring-Straße 76
35041 Marburg / DE
Former [2023/26]
Opponent(s)01  24.03.2020  26.03.2020  ADMISSIBLE
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
Opponent's representative
Wichmann, Hendrik
Wuesthoff & Wuesthoff
Patentanwälte PartG mbB
Schweigerstraße 2
81541 München / DE
 02  26.03.2020  30.03.2020  ADMISSIBLE
Pfizer Inc.
235 East 42nd Street
New York, NY 10017 / US
Opponent's representative
Pfizer
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
 03  26.03.2020  30.03.2020  ADMISSIBLE
Grund, Dr., Martin
Nikolaistr. 15
80802 Munich / DE
Opponent's representative
Grund, Martin
Grund Intellectual Property Group
Patentanwälte und Solicitor PartG mbB
Steinsdorfstraße 2
80538 München / DE
 04  17.04.2020  24.05.2023  WITHDRAWN
Friedrich, Rainer
Breuer Friedrich Hahner Patentanwälte PartG mbB
Brienner Straße 1
80333 München / DE
Opponent's representative
Friedrich, Rainer
CSL Behring GmbH
Emil-von-Behring-Straße 76
35041 Marburg / DE
Former [2022/18]
Opponent(s)01  24.03.2020  26.03.2020  ADMISSIBLE
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
Opponent's representative
Wichmann, Hendrik
Wuesthoff & Wuesthoff
Patentanwälte PartG mbB
Schweigerstraße 2
81541 München / DE
 02  26.03.2020  30.03.2020  ADMISSIBLE
Pfizer Inc.
235 East 42nd Street
New York, NY 10017 / US
Opponent's representative
Pfizer
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
 03  26.03.2020  30.03.2020  ADMISSIBLE
Grund, Dr., Martin
Nikolaistr. 15
80802 Munich / DE
Opponent's representative
Grund, Martin
Grund Intellectual Property Group
Patentanwalt und Solicitor PartG mbB
Postfach 44 05 16
80754 München / DE
 04  17.04.2020  22.04.2020  ADMISSIBLE
Friedrich, Rainer
Breuer Friedrich Hahner Patentanwälte PartG mbB
Brienner Straße 1
80333 München / DE
Opponent's representative
Friedrich, Rainer
Brienner Straße 1
80333 München / DE
Former [2020/22]
Opponent(s)01  24.03.2020  26.03.2020  ADMISSIBLE
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
Opponent's representative
Wichmann, Hendrik
Wuesthoff & Wuesthoff
Patentanwälte PartG mbB
Schweigerstraße 2
81541 München / DE
 02  26.03.2020  30.03.2020  ADMISSIBLE
Pfizer Inc.
235 East 42nd Street
New York, NY 10017 / US
Opponent's representative
Pfizer
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
 03  26.03.2020  30.03.2020  ADMISSIBLE
Grund, Dr., Martin
Nikolaistr. 15
80802 Munich / DE
Opponent's representative
Grund, Martin
Grund Intellectual Property Group
Patentanwalt und Solicitor PartG mbB
Postfach 44 05 16
80754 München / DE
 04  17.04.2020  22.04.2020  ADMISSIBLE
Friedrich, Rainer
Breuer Friedrich Hahner Patentanwälte PartG mbB
Brienner Straße 1
80333 München / DE
Opponent's representative
Friedrich, Rainer
Breuer Friedrich Hahner
Patentanwälte PartG mbB i. Gr.
Brienner Strasse 1
80333 München / DE
Former [2020/19]
Opponent(s)01  24.03.2020  26.03.2020  ADMISSIBLE
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
Opponent's representative
Wichmann, Hendrik
Wuesthoff & Wuesthoff
Patentanwälte PartG mbB
Schweigerstraße 2
81541 München / DE
 02  26.03.2020  30.03.2020  ADMISSIBLE
Pfizer Inc.
235 East 42nd Street
New York, NY 10017 / US
Opponent's representative
Pfizer
European Patent Department
23-25 avenue du Docteur Lannelongue
75668 Paris Cedex 14 / FR
 03  26.03.2020  30.03.2020  ADMISSIBLE
Grund, Dr., Martin
Nikolaistr. 15
80802 Munich / DE
Opponent's representative
Grund, Martin
Grund Intellectual Property Group
Patentanwalt und Solicitor PartG mbB
Postfach 44 05 16
80754 München / DE
Former [2020/18]
Opponent(s)01  24.03.2020  26.03.2020  ADMISSIBLE
Merck Sharp & Dohme Corp.
126 East Lincoln Avenue
Rahway, NJ 07065-0907 / US
Opponent's representative
Wichmann, Hendrik
Wuesthoff & Wuesthoff
Patentanwälte PartG mbB
Schweigerstraße 2
81541 München / DE
17.06.2020Invitation to proprietor to file observations on the notice of opposition
27.11.2020Reply of patent proprietor to notice(s) of opposition
01.12.2021Date of oral proceedings
24.01.2022Despatch of minutes of oral proceedings
24.01.2022Despatch of communication that the patent will be revoked
27.06.2024Legal effect of revocation of patent [2024/31]
Appeal following opposition24.03.2022Appeal received No.  T0787/22
24.03.2022Payment of appeal fee
03.06.2022Statement of grounds filed
26.06.2024Result of appeal procedure: REVOCATION OF PATENT AT PROPRIETOR'S REQUEST
27.06.2024Despatch of the decision of the Board of Appeal
Fees paidRenewal fee
02.03.2018Renewal fee patent year 03
20.03.2019Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU22.04.2016
AL26.06.2019
CY26.06.2019
CZ26.06.2019
EE26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
MC26.06.2019
MK26.06.2019
MT26.06.2019
PL26.06.2019
RO26.06.2019
RS26.06.2019
SI26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
BG26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
LU22.04.2020
NO30.04.2024
[2025/08]
Former [2022/33]HU22.04.2016
AL26.06.2019
CY26.06.2019
CZ26.06.2019
EE26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
MC26.06.2019
MK26.06.2019
MT26.06.2019
PL26.06.2019
RO26.06.2019
RS26.06.2019
SI26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
BG26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
LU22.04.2020
Former [2022/28]HU22.04.2016
AL26.06.2019
CY26.06.2019
CZ26.06.2019
EE26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
MC26.06.2019
MT26.06.2019
PL26.06.2019
RO26.06.2019
RS26.06.2019
SI26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
BG26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
LU22.04.2020
Former [2021/08]AL26.06.2019
CZ26.06.2019
EE26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
MC26.06.2019
PL26.06.2019
RO26.06.2019
RS26.06.2019
SI26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
BG26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
LU22.04.2020
Former [2020/52]AL26.06.2019
CZ26.06.2019
EE26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
MC26.06.2019
PL26.06.2019
RO26.06.2019
RS26.06.2019
SI26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
BG26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
Former [2020/37]AL26.06.2019
CZ26.06.2019
EE26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
PL26.06.2019
RO26.06.2019
RS26.06.2019
SI26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
BG26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
Former [2020/36]AL26.06.2019
CZ26.06.2019
EE26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
PL26.06.2019
RO26.06.2019
RS26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
BG26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
Former [2020/24]AL26.06.2019
CZ26.06.2019
EE26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
PL26.06.2019
RO26.06.2019
RS26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
BG26.09.2019
GR27.09.2019
PT28.10.2019
IS24.02.2020
Former [2020/17]AL26.06.2019
CZ26.06.2019
EE26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
RO26.06.2019
RS26.06.2019
SK26.06.2019
SM26.06.2019
TR26.06.2019
BG26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
Former [2020/14]AL26.06.2019
CZ26.06.2019
EE26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
RO26.06.2019
RS26.06.2019
SK26.06.2019
SM26.06.2019
BG26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
Former [2020/12]AL26.06.2019
CZ26.06.2019
EE26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
RO26.06.2019
RS26.06.2019
SK26.06.2019
BG26.09.2019
GR27.09.2019
IS26.10.2019
PT28.10.2019
Former [2020/11]AL26.06.2019
CZ26.06.2019
EE26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
RO26.06.2019
RS26.06.2019
SK26.06.2019
BG26.09.2019
GR27.09.2019
PT28.10.2019
Former [2020/10]AL26.06.2019
CZ26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
RO26.06.2019
RS26.06.2019
BG26.09.2019
GR27.09.2019
PT28.10.2019
Former [2020/09]AL26.06.2019
CZ26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
RS26.06.2019
BG26.09.2019
GR27.09.2019
Former [2019/51]AL26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
RS26.06.2019
BG26.09.2019
GR27.09.2019
Former [2019/50]AL26.06.2019
HR26.06.2019
LT26.06.2019
LV26.06.2019
RS26.06.2019
GR27.09.2019
Former [2019/47]LT26.06.2019
Documents cited:Search[YD]WO02098443  (VON DER MUELBE FLORIAN [DE], et al);
 [Y]WO2006024518  (CUREVAC GMBH [DE], et al);
 [XYI]WO2009095226  (CUREVAC GMBH [DE], et al);
 [XDYI]WO2012013326  (CUREVAC GMBH [DE], et al);
 [XYI]EP2623121  (BAYER INNOVATION GMBH [DE], et al);
 [XDYI]WO2014127917  (CUREVAC GMBH [DE]);
by applicantWO9512673
 WO9521251
 WO9521915
 EP1083232
 WO02098443
 WO03051401
 WO03086280
 WO2006008154
 US7074596
 WO2008016473
 WO2008077592
 WO2008083949
 WO2008157688
 WO2009030481
 WO2009149253
 WO2010037539
 WO2011015347
 WO2011026641
 WO2012013326
 WO2012019780
 WO2012113513
 WO2012116811
 WO2013059475
 WO2013143700
 WO2014127917
 WO2014189805
OppositionWO2009095226
 WO2012013326
 WO2012113513
 EP2623121
 WO2011003883
 WO2017085228
 WO02098443
 WO2014127917
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.